How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme
- 20 January 2022
- journal article
- review article
- Published by Springer Nature in Pharmacological Reports
- Vol. 74 (2) , 323-339
Abstract
Since the discovery of phosphodiesterase-5 (PDE5) enzyme overexpression in the central nervous system (CNS) malignancies, investigations have explored the potential capacity of current PDE5 inhibitor drugs for repositioning in the treatment of brain tumors, notably glioblastoma multiforme (GBM). It has now been recognized that these drugs increase brain tumors permeability and enhance standard chemotherapeutics effectiveness. More importantly, studies have highlighted the promising antitumor functions of PDE5 inhibitors, e.g., triggering apoptosis, suppressing tumor cell growth and invasion, and reversing tumor microenvironment (TME) immunosuppression in the brain. However, contradictory reports have suggested a pro-oncogenic role for neuronal cyclic guanosine monophosphate (cGMP), indicating the beneficial function of PDE5 in the brain of GBM patients. Unfortunately, due to the inconsistent preclinical findings, only a few clinical trials are evaluating the therapeutic value of PDE5 inhibitors in GBM treatment. Accordingly, additional studies should be conducted to shed light on the precise effect of PDE5 inhibitors in GBM biology regarding the existing molecular heterogeneities among individuals. Here, we highlighted and discussed the previously investigated mechanisms underlying the impacts of PDE5 inhibitors in cancers, focusing on GBM to provide an overview of current knowledge necessary for future studies.Keywords
This publication has 205 references indexed in Scilit:
- Restoring Soluble Guanylyl Cyclase Expression and Function Blocks the Aggressive Course of GliomaMolecular Pharmacology, 2011
- Roles of Sildenafil in Enhancing Drug Sensitivity in CancerCancer Research, 2011
- The Hippo Signaling Pathway in Development and CancerDevelopmental Cell, 2010
- Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunctionProceedings of the National Academy of Sciences, 2010
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP ActionPharmacological Reviews, 2010
- Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with CautionAdvances in Urology, 2009
- Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3βJournal of Biological Chemistry, 2008
- PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor modelBrain Research, 2008
- Elucidation of a Universal Size-Control Mechanism in Drosophila and MammalsCell, 2007
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionJournal of Experimental Medicine, 2006